The Proteomics Shared Resource provides analytical proteomics services to investigators in the VICC. Proteomics is the study of proteomes, which are the functional complements to genomes and which comprise diverse structural and catalytically functional multiprotein machines. Proteomics approaches offer new tools for the molecular analysis of cancer, the identification of therapeutic targets and mechanisms, and to identify markers for disease and therapeutic response. Analytical proteomics integrates tools for protein and peptide separations, MS analysis and bioinformatics to characterize proteomes and their component proteins. A unique feature of the Proteomics Shared Resource is the availability of all major proteomics analysis technologies, which offers exceptional flexibility in analytical approaches. It provides the following services: identification of proteins in both simple and complex multiprotein samples; analyses of protein modifications; analyses of differential protein expression and modification; development and implementation of methods to detect serum markers for tumors, therapeutic susceptibility and response; providing expertise and training in proteomics analysis and experimental design to VICC investigators; and facilitating the transition of new technology into proteomics research. Dr. Daniel C. Liebler serves as Scientific Director. A recent recruit to the VICC, he previously established a successful Proteomics Shared Resource in the Southeast Environmental Health Sciences Center and Arizona Cancer Center at the University of Arizona. The staff of the Shared Resource have specialized expertise that enable them assist investigators with coverage of a vast number of new technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-13
Application #
7679664
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
13
Fiscal Year
2008
Total Cost
$461,108
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Garcia, A Denise R; Han, Young-Goo; Triplett, Jason W et al. (2018) The Elegance of Sonic Hedgehog: Emerging Novel Functions for a Classic Morphogen. J Neurosci 38:9338-9345

Showing the most recent 10 out of 2462 publications